Hydrogen-powered refrigeration system for environmentally friendly transport and delivery in the food supply chain

Urban population and the trend towards online commerce leads to an increase in delivery solution in cities. The growth of the transport sector is very harmful to the environment, being responsible for approximately 40% of greenhouse gas emissions in the European Union. The problem is aggravated when transporting perishable foodstuffs, as the vehicle propulsion engine (VPE) must power not only the vehicle but also the refrigeration unit. This means that the VPE must be running continuously, both on the road and stationary (during delivery), as the cold chain must be preserved. The result is costly (high fuel consumption) and harmful to the environment. At present, refrigerated transport does not support full-electric solutions, due to the high energy consumption required, which motivates the work presented in this article. It presents a turnkey solution of a hydrogenpowered refrigeration system (HPRS) to be integrated into standard light trucks and vans for short-distance food transport and delivery. The proposed solution combines an air-cooled polymer electrolyte membrane fuel cell (PEMFC), a lithium-ion battery and low-weight pressurised hydrogen cylinders to minimise cost and increase autonomy and energy density. In addition, for its implementation and integration, all the acquisition, power and control electronics necessary for its correct management have been developed. Similarly, an energy management system (EMS) has been developed to ensure continuity and safety in the operation of the electrical system during the working day, while maximizing both the available output power and lifetime of the PEMFC. Experimental results on a real refrigerated light truck provide more than 4 h of autonomy in intensive intercity driving profiles, which can be increased, if necessary, by simply increasing the pressure of the stored hydrogen from the current 200 bar to whatever is required. The correct operation of the entire HPRS has been experimentally validated in terms of functionality, autonomy and safety; with fuel savings of more than 10% and more than 3650 kg of CO2/ year avoided.This work is a contribution of the two following Projects: “H2Integration& Control. Integration and Control of a hydrogen-based pilot plant in residential applications for energy supply”, Ref. PID2020-116616RB-C31 supported by the Spanish State Program of R + D + I Oriented to the Challenges of Society; and “SALTES: Smartgrid with reconfigurable Architecture for testing controL Techniques and Energy Storage priority contaminant waste”, Ref. P20-00730 supported by Andalusian Regional Program of R + D + I. Funding for open access charge: Universidad de Huelva/CBUA

Whole transcription profile of responders to anti-tnf drugs in pediatric inflammatory bowel disease

Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. Methods: An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged 0.6 or <−0.6 and p value < 0.05). After validation, FCGR1A, FCGR1B, and GBP1 were overexpressed in non-responders two weeks after initiation of anti-TNF treatment (Log2FC 1.05, 1.21, and 1.08, respectively, p value < 0.05). Conclusion: Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBDInstituto de Salud Carlos III número de becas PI16 / 00559 y PI19 / 00792Consejería de Educación y Deporte de la Comunidad de Madrid PEJ16 / MED / AI-1260Instituto de Investigaciones Sanitarias Gregorio Marañón PRE2018-2Fondos Europeos de Desarrollo Regional (FEDER) del Comisión Europe

Plan De Responsabilidad Social Para La Empresa Almacenes Éxito

Codigo de Etica, (Formato de Recolección de Información)El presente documento de Plan de Responsabilidad Social de la empresa Almacenes Éxito, es vital para el posicionamiento de la organización en las diferentes orbitas de un manejo empresarial (económico, social, ambiental), es así, como se utilizaron diferentes herramientas para recoger y almacenar la mayor cantidad de datos de los clientes y así evaluar el impacto de las políticas de responsabilidad social frente a ellos, entonces, para poder llevar a una ejecución efectiva y sobre todo relevante para la compañía en cuanto al posicionamiento de las políticas de responsabilidad social, es menester tomar en consideración todos los instrumentos que ayuden en la consecución de dicho objetivo, como fue realizar un Diagnostico acorde a la realidad social y empresarial desde él ya mencionado recolección y almacenamiento hasta la aplicación del plan por parte de la empresa, sin dejar de lado elementos tan importantes como lo son el derecho comparado, los Códigos de Ética y obviamente y seguimiento y control estricto para alcanzar los objetivos planteados, por último, el plan de responsabilidad social para la empresa almacenes Éxito planteado no solo busca resultados a corto y mediano plazo sino una retroalimentación constante que lleve a reprogramar y reconstruir el plan de acción a medida que los resultados así demuestren para que el plan sea una construcción permanente y con resultados favorables para cada uno de los involucrados.This document of the Social Responsibility Plan of the company Almacenes Éxito is vital for the positioning of the organization in the different areas of business management (economic, social, environmental), this is how different tools were used to collect and store the largest amount of customer data and thus assess the impact of social responsibility policies against them, then, in order to carry out an effective execution and above all relevant for the company in terms of the positioning of social responsibility policies, It is necessary to take into consideration all the instruments that help in achieving this objective, such as making a Diagnosis according to the social and business reality from the aforementioned collection and storage to the application of the plan by the company, without ceasing to side elements as important as comparative law, the Codes of Ethics and obviously and strict control and control to achieve the objectives, finally, the social responsibility plan for the company Éxito warehouses not only seeks results in the short and medium term but also a constant feedback that leads to reprogramming and rebuilding the action plan as The results thus demonstrate so that the plan is a permanent construction and with favorable results for each one of those involved

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial

Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in desperate situations. It is one of the so-called neglected antibiotics of high potential interest for the future. Methods and analysis The main objective of this project is to demonstrate the clinical non-inferiority of intravenous fosfomycin with regard to meropenem for treating bacteraemic urinary tract infections (UTI) caused by ESBL-EC. This is a ‘real practice’ multicentre, open-label, phase III randomised controlled trial, designed to compare the clinical and microbiological efficacy, and safety of intravenous fosfomycin (4 g/6 h) and meropenem (1 g/8 h) as targeted therapy for this infection; a change to oral therapy is permitted after 5 days in both arms, in accordance with predetermined options. The study design follows the latest recommendations for designing trials investigating new options for multidrug-resistant bacteria. Secondary objectives include the study of fosfomycin concentrations in plasma and the impact of both drugs on intestinal colonisation by multidrug-resistant Gram-negative bacilli. Ethics and dissemination Ethical approval was obtained from the Andalusian Coordinating Institutional Review Board (IRB) for Biomedical Research (Referral Ethics Committee), which obtained approval from the local ethics committees at all participating sites in Spain (22 sites). Data will be presented at international conferences and published in peer-reviewed journals. Discussion This project is proposed as an initial step in the investigation of an orphan antimicrobial of low cost with high potential as a therapeutic alternative in common infections such as UTI in selected patients. These results may have a major impact on the use of antibiotics and the development of new projects with this drug, whether as monotherapy or combination therapy

Responsabilidad profesional

12 p.En el siguiente análisis se quiere dar a conocer todos aquellos aspectos relacionados con el profesional de la carrera de derecho y sus faltas por medio de un caso, donde de acuerdo con la Sentencia 470011102000200700332 01 el señor Orlando López Pérez presentó el 4 de octubre de 2007 queja disciplinaria en contra de los abogados Luis Eduardo Ramos Carrillo y Guillermo Rafael Villa Robles, dado que el señor Orlando López el día 20 de noviembre de 2006 otorgó poder al doctor Guillermo Rafael Villa Robles para que instaurara proceso ordinario laboral contra el Instituto de Seguro Social y obtener así el pago de su pensión de vejez junto con sus respectivos retroactivos e intereses, correspondiéndole este proceso en reparto al Juzgado Primero Laboral del Circuito de Ciénega Magdalena; el proceso culminó con sentencia favorable el día 22 de julio de 2007, condenando a la entidad demandada al pago de la suma de $63.720.630.94, el 24 de julio de 2007 Juzgado Primero Laboral del Circuito de Ciénega Magdalena, libró mandamiento de pago dentro del mismo proceso como ejecución de la sentencia por la suma de$154.102.376.70 más los intereses moratorios, agencias en derecho y otros conceptos arrojando en su totalidad la suma de $164.443.501.78, suma que fue cobrada mediante título judicial N° 54197 por el doctor Luis Eduardo Ramos Carrillo, a quien se le había sustituido poder en el proceso, en muchas ocasiones el señor Orlando López, le preguntó al doctor Guillermo Rafael Villa Robles cuánto le iba a cobrar por concepto de honorarios y que nunca contestó, y que luego de terminado el proceso lo cita a su oficina y le hace entrega de la suma de$17.000.000, firmándole un recibo del cual no recibió copia alguna; inconforme con el valor recibido, el señor Orlando López solicita se investigue a los abogados denunciados por cobrar como honorarios la suma de $147.443.501.78, suma que le parece injusta, pues solo recibió$17.000.000.I. INTRODUCCIÓN II. ANÁLISIS III. RESUMEN DEL CASO CONCRETO IV. ANÁLISIS V. CONCLUSIÓN BIBLIOGRAFÍ

Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease

T. Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged &lt;18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value &lt; 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.This work was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE-2018-2), The study was cofunded by ERDF Funds (FEDER) from the European Commission, “A way of making Europe

Temas Socio-Jurídicos. Volumen 15 No. 33 Diciembre de 1997

La edición número 33 de la revista temas socio-jurídicos pone a consideración de sus lectores, los trabajos elaborados por docentes y estudiantes de la Facultad de Derecho de la Universidad Autónoma de Bucaramanga, en éste, su vigésimoquinto año de funcionamiento.The 33rd edition of the socio-legal issues magazine presents to its readers the works prepared by teachers and students of the Faculty of Law of the Autonomous University of Bucaramanga, in its twenty-fifth year of operation

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections

IMPORTANCE The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. OBJECTIVE To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. INTERVENTIONS Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or pa renteral ertapenem for the comparator group after 4 days. MAIN OUTCOMES AND MEASURES The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. RESULTS Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to infinity percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI. -infinity to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01). CONCLUSIONS AND RELEVANCE This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections

Generations UNAB No.4

Esta cuarta edición de la revista Generaciones UNAB, gira en torno a la celebración de los 40 años de inicio de labores de la Facultad de Derecho, cuyo primeros 25 graduados obtuvieron su título en 1978; así como a la celebración de los primeros 30 años de inicio de labores de la Facultad de Comunicación Social que graduó a sus primeros 17 estudiantes en 1987. Hoy, cuatro y tres décadas después del inicio de labores respectivamente, y atendiendo al compromiso institucional con la región, ña Universidad ha permitido que Santander, Colombia y el mundo cuenten con 3.104 abogados y 1.647 comunicadores sociales que se destacan por su compromiso con la sociedad, su trabajo en equipo, ética y valores en el ejercicio profesional.Editorial; Por Marcela Peralta Bautista…03 Columnista invitado, Facultades bien dirigidas; Por Alfonso Gómez Gómez…06 40 años de la Facultad de Derecho…08 Cuatro décadas formando futuro; Por José Manuel Arias Carrizosa…09 Una facultad de libertadores; Por Jaime Gutiérrez Rivero…10 Defendiendo la libertad del conocimiento; Por Sergio Rangel Consuegra…11 La cara humana del derecho; Por Jorge González Aranda…13 La decanatura marcó mi vida; Por Gabriel Burgos Mantilla…14 La unión hace la fuerza; Por Jorge Castillo Rugeles…16 Mis estudiantes son lo más importante; Por Rodolfo Mantilla Jácome…18 La hermenéutica jurídica como sello diferenciador; Por Juan Carlos Acuña Gutiérrez...20 Equipo de trabajo y apoyo directivo; Por Jorge Eduardo Lamo Gómez…22 30 años de la Facultad de Comunicación Social…25 Haciendo el sueño realidad; Por Carlos H. Gómez…26 Un compromiso de vida; Por Maria Isabel León Carreño…28 Construir debatiendo; Por Rodrigo Velasco Ortiz…30 La importancia de potenciar capacidades; Por Luz Amalia Camacho Velásquez...32 Una propuesta académica única; Por Iván Darío Montoya Osorio…34 Graduados Destacando…37 Docente en la Facultad de Derecho UNAB…38 Comunicación Social-Periodista de la UNAB; Por Sonia Díaz…39 Emprendedores UNAB “Apps.com”; Por Marcela Peralta Bautista…40 Instigación “Trata de personas”; Por Lya Fernández de Mantilla, Johana Marcela Reyes…42 Encuentros…45This fourth edition of the magazine Generaciones UNAB, revolves around the celebration of 40 years of beginning of work of the Faculty of Law, whose first 25 graduates obtained their degree in 1978; as well as the celebration of the first 30 years of beginning of work of the Faculty of Social Communication that graduated its first 17 students in 1987. Today, four and three decades after the start of work respectively, and in response to the institutional commitment to the region, ña University has allowed Santander, Colombia and the world to have 3,104 lawyers and 1,647 social communicators who stand out for their commitment to society , their teamwork, ethics and values ​​in professional practice

Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease

Around a 20–30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2−∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies